Background: Hallucinations are prevalent in schizophrenia and related psychotic ... the anti-hallucinatory effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone with up to 2 ...

New data from Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) show favorable patient and healthcare ...

The mean modal dose of olanzapine for the black patient group ... of all-cause time to discontinuation in the treatment of schizophrenia as a proxy measure for treatment effectiveness (primary ...

Results from the SOLARIS trial survey showed that over 92% of patients, 87% of nurses, and 72% of physicians expressed satisfaction with TEV-'749’s initiation regimen, dosing schedule, and overall ...

Olanzapine is used in the treatment of schizophrenia (a mental disorder that can result in hallucinations or delusions and also adversely affects a person’s ability to think and behave ...

Olanzapine is one of the most widely prescribed second-generation antipsychotics for schizophrenia. No cases of post-injection delirium or sedation syndrome have been seen to date, and more safety ...

With nearly 30 years of clinical and real-world use, olanzapine is one of the most commonly prescribed second-generation oral antipsychotics for the treatment of schizophrenia globally ...

is a subcutaneous long-acting form of a common schizophrenia medication — in this case, olanzapine. “Olanzapine has been out for 30+ years, but what’s different here is that we’ve used our ...

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1.

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1. These ...